Advertisement

Topics

Latest "Use Of New Supraglottic Airway Devices In Severely Obese Patients: A Feasibility Study" News Stories

10:34 EST 17th November 2018 | BioPortfolio

Here are the most relevant search results for "Use Of New Supraglottic Airway Devices In Severely Obese Patients: A Feasibility Study" found in our extensive news archives from over 250 global news sources.

More Information about Use Of New Supraglottic Airway Devices In Severely Obese Patients: A Feasibility Study on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Use Of New Supraglottic Airway Devices In Severely Obese Patients: A Feasibility Study for you to read. Along with our medical data and news we also list Use Of New Supraglottic Airway Devices In Severely Obese Patients: A Feasibility Study Clinical Trials, which are updated daily. BioPortfolio also has a large database of Use Of New Supraglottic Airway Devices In Severely Obese Patients: A Feasibility Study Companies for you to search.

Showing "Supraglottic Airway Devices Severely Obese Patients Feasibility Study" News Articles 1–25 of 40,000+

Saturday 17th November 2018

United States Airway and Anesthesia Procedures Outlook to 2025 [Report Updated: 01102018] Prices from USD $2995

United States Airway and Anesthesia Procedures Outlook to 2025SummaryGlobalData's new report, United States Airway and Anesthesia Procedures Outlook to 2024, provides key procedures data on the United States Airway and Anesthesia Procedures. The report provides procedure volumes within market segments Airway Management Procedures, Anesthesia Circuit Procedures, Anesthesia Mask Procedures, Breathi...


Agios Pharmaceuticals Inc AGIO Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23102018] Prices from USD $250

SummaryAgios Pharmaceuticals Inc Agios is a biopharmaceutical company that focuses on the discovery and development of investigational medicines for the treatment of cancer and rare genetic metabolic disorders. The company's products include IDHIFA, an oral targeted inhibitor of the mutated IDH2 enzyme used for the treatment of patients with R/R acute myeloid leukemia AML; and TIBSOVO ivosidenib, ...

hVIVO Plc HVO Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23102018] Prices from USD $250

SummaryhVIVO Plc hVIVO, formerly Retroscreen Virology Ltd is a biopharma company that develops humanbased analytical platform to accelerate drug discovery and development. The company enables organisations to discover drugs and diagnostics and accelerate new product development. It uses human disease model platform to study new drugs and investigate diseases. hVIVO offers services such as viral ch...


Dabrafenib Plus Trametinib Demonstrates Activity in GI Cancers

The combination of dabrafenib and trametinib led to encouraging responses in patients with rare, incurable cancer of the digestive tract.

What May Happen To Allergies If You Suck On Your Infant's Pacifier

When your baby's pacifier drops to the ground, do you clean it with your mouth and put it back in the baby's mouth? Does this study really suggest that this may help prevent allergies in your baby?

Friday 16th November 2018

What is the difference between rate, risk and odds?

Oftentimes, you will ready a study that says, treatment A reduces the rate of something by X%, or the treatment reduces the risk by Y%, or reduces the odds by Z%.  These are basically the same thing, right? That is not entirely correct.  While all these concepts summarize the frequency or likelihood of something occuring…

Digital Landscape: Inflammatory Bowel Disease [Report Updated: 06092018] Prices from USD $6000

Digital Landscape: Inflammatory Bowel DiseaseSummaryThe Digital Landscape Inflammatory Bowel Disease report analyzes digital activities undertaken by pharma in support of diseasemodifying therapies for mildtomoderate, and moderatetosevere Crohn's disease and ulcerative colitis UC.Key Highlights US Patients: AbbVie offers the strongest support for IBD patients in the US, particularly branded, unbra...

Women’s Excellence in Rochester, Michigan Now Offers Treatment Plans for Women with Pelvic Pain

Women's Excellence specializes in the diagnosis and treatment of chronic pelvic pain. ROCHESTER, Mich. (PRWEB) November 16, 2018 Women’s Excellence in Rochester, Michigan, will now offer treatment options to patients suffering from chronic pelvic pain. In addition to oncology services, the new center will specialize in the diagnosis and treatment of various pelvic pain disorders including e...

Women’s Excellence Now Offers Treatment Plans for Patients with Persistent Vaginal Discharge

Women's Excellence specialize in vaginal conditions, like Vaginitis, and will develop a personalized treatment plan to eliminate your symptoms. LAKE ORION, Mich. (PRWEB) November 16, 2018 Most of the time, vaginal discharge is perfectly normal and an essential function in the female reproductive system. However, changes in the color, smell, or consistency could be signs of an infections or an...

. @LifeAtPurdue investigators develop technology to help deliver #Cancer treatment while easing the painful side effects of #chemotherapy on patients: http://ow.ly/qT5F30mDZ8N 

. @LifeAtPurdue investigators develop technology to help deliver #Cancer treatment while easing the painful side effects of #chemotherapy on patients: http://ow.ly/qT5F30mDZ8N 

Congratulations on 10 Fantastic Years - Meet Laya Dogmetchi, Member of the Board of Directors

GRACE celebrates 10 years as a non profit! Meet the dedicated staff and board who work so hard to bring this amazing site to life.Laya Dogmetchi, Board Member

Factors associated with viral non-suppression among adolescents living with HIV in Cambodia: a cross-sectional study

Adolescents living with HIV on antiretroviral therapy (ART) have worse treatment adherence, viral suppression, and mortality rates compared to adults. This study investigated factors associated with viral non-...

Castlight Health Inc CSLT Medical Equipment Deals and Alliances Profile [Report Updated: 23102018] Prices from USD $250

SummaryCastlight Health Inc Castlight provides an online health navigation platform that connects patients with health vendors, plan designs, and benefit resources. The platform allows patients to view and compare the prices of medical services and surgeries from multiple health providers. It offers includes engagement hub, wellbeing programs, and care guidance virtual assistant for simplifying ca...

Novartis' blood disorder drug gets FDA approval for expanded use

Novartis AG said on Friday the U.S. Food and Drug Administration expanded the use of its low platelets drug to treat patients with a rare, genetic blood disorder.

Axikin Pharmaceuticals Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27092018] Prices from USD $250

SummaryAxikin Pharmaceuticals Inc Axikin is a biopharmaceutical company that develops small molecule therapeutics for respiratory disorders. The company offers preclinical and research programs with small molecule therapeutics for applications in asthma, chronic obstructive pulmonary disease, inflammatory dermatoses, inflammatory bowel disease, and rheumatoid arthritis. Its research areas include ...

FDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designation for additional new indication

Novartis International AG / FDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designation for additional new indication . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. Promacta receives FDA approval for first-line treatment of severe aplastic anemia (SAA) and Breakthro...

Novel Agent Active Across Heavily Pretreated HER2+ Tumors

The novel bispecific antibody ZW25 induced a disease control rate of 82% in heavily pretreated patients across several HER2-positive tumor types, according to phase I study results presented at the 2018 EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium.

Capivasertib Effective in AKT-Mutated Cancers

The investigational AKT inhibitor capivasertib (AZD5363) demonstrated clinical activity in patients with AKT-mutated cancers, suggesting the validity of tailoring treatment to tumor genes. 

Make-a-Wish program tied to lower hospital costs for sick kids

(Reuters Health) - Kids with life-threatening illnesses who receive a special gift from the Make-a-Wish Foundation may have lower hospital costs than sick children who don't get these gifts, a U.S. study suggests.

FDA Approves Frontline Eltrombopag for Severe Aplastic Anemia

The FDA has expanded the approval of eltrombopag in combination with standard immunosuppressive therapy to include newly diagnosed adult and pediatric patients 2 years and older with severe aplastic anemia.

World Institute of Kimchi: Function-enhanced kimchi inhibits growth of cancer cells

Proven anticancer effects of Amtak Baechu cabbage, a crossbred of turnip and Baechu cabbage Intake of kimchi made with Amtak Baechu cabbage doubles the rate of pancreatic cancer cell inhibition compared with standard kimchi SEOUL, South Korea, Nov. 16, 2018 /PRNewswire/ -- Worl

Milk allergy most common in kids under 5, study says

Milk is the most common food allergy for children under 5, but a new study says many cases are not diagnosed and parents are unprepared.

Nivolumab/Ipilimumab Combo Nears EU Approval for Frontline RCC

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended approval of nivolumab combined with low-dose ipilimumab as a frontline treatment for patients with intermediate- and poor-risk advanced renal cell carcinoma.

Study: AI tool detects skin cancers better than dermatologists

An AI-based network outperformed several dermatologists while analyzing skin lesions for cancer, suggesting the technology could be a helpful tool for physicians regardless of their experience, according to a recent study.

Eleventh child dies from viral outbreak at New Jersey facility

An 11th child has died in less than four weeks at a New Jersey rehabilitation center, one of 34 young patients with compromised immune systems to have been infected by a viral outbreak, state health officials said on Friday.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks